Multi-Cancer Early Detection Blood Tests Nearing FDA Approval and Clinical Use
Key Questions
Which multi-cancer blood tests are nearing wider clinical use?
The Galleri test screens for 50 cancers, while the Shield test targets colorectal cancer. Both are advancing toward broader adoption through regulatory and payer milestones.
What coverage has the Shield test received for colorectal cancer screening?
UnitedHealth now covers the Shield test for eligible members aged 45 and older. This expands access to a convenient blood-based option for colon cancer screening.
Is the Shield test FDA-approved?
Yes, the Shield test has received FDA approval for colorectal cancer screening. It is being promoted during Men’s Health Month as an easier screening method.
How do these blood tests represent a breakthrough in cancer detection?
They offer non-invasive, blood-based screening for multiple cancers, including colorectal, at earlier stages. This supports preventive oncology and improves accessibility compared with traditional methods.
Who can benefit from the Shield test under the new UnitedHealth coverage?
Eligible UnitedHealth members aged 45 and older can access the Shield test for colorectal cancer screening. The coverage aims to increase screening rates through a simple blood draw.
The Galleri test (50 cancers) and the Shield test (colorectal cancer) are blood-based screening tools approaching wider adoption. The Shield test is FDA-approved and promoted during Men's Health Month. These represent a major breakthrough in preventive oncology and blood-based diagnostics, directly relevant to blood markers and cancer screening.